Recent Updates — NXGL

NexGel, Inc. filed a Certificate of Amendment to its Certificate of Incorporation with the State of Delaware on October 7, 2026, to effect a one-for-twenty reverse stock split of its common stock. The transaction becomes effective at 12:01 a.m. Eastern Time on October 12, 2026. Under the terms, every twenty shares held prior to the effective time are combined into one share. Fractional shares resulting from the split will be rounded up to the nearest whole share rather than paid out in cash. The company's common stock will continue trading on the Nasdaq Capital Market under the symbol NXGL with a new CUSIP number, while the par value remains $0.001 per share. NexGel develops and manufactures medical devices for wound care and tissue regeneration.

NexGel, Inc. held its Special Meeting of Stockholders on September 23, 2026, where shareholders approved two key proposals. First, they authorized an amendment to the Certificate of Incorporation to increase the number of authorized common shares from 25,000,000 to up to 150,000,000 at the Board's discretion for one year. Second, shareholders approved a discretionary reverse stock split with a ratio ranging from 1-for-2 to 1-for-20, also at the Board's discretion within one year of approval. The company operates in the medical device industry, specifically focusing on regenerative medicine and tissue engineering solutions.

NexGel, Inc. entered into a new Executive Employment Agreement with President and CEO Adam Levy on July 23, 2026, superseding his prior agreement that expired December 31, 2025. The contract establishes an annual base salary of $375,000 and includes discretionary cash bonuses up to $25,000 plus performance-based EBITDA targets ranging from $4 million to $8 million. Levy received a grant of options to purchase 160,000 shares at an exercise price of $0.647, with vesting scheduled for December 31, 2026, and monthly installments thereafter. The agreement provides twelve months of severance benefits upon termination without cause or for good reason, including accelerated equity vesting. NexGel, Inc. operates in the medical device industry, specializing in non-invasive therapies for pain management.